All In Biotech

Drug Trial Radar · NCT06717815

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

A Multi-center, Multi-dose Phase Ib/IIa Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Impact on Biomarkers of IPG11406 in Patients With Lupus Nephritis

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Feb 25, 2025

Primary completion

Jun 8, 2026

Study completion Jun 8, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

Conditions

  • Lupus Nephritis

Interventions

  • IPG11406Drug

    Investigational Medical Products: IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage:15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability via assessment of Adverse eventsTime frame: Up to 58 days
  2. Evaluate the safety and tolerability via Respiration rate of Vital SignsTime frame: Up to 58 days
  3. Evaluate the safety and tolerability via Heart rate of Vital SignsTime frame: Up to 58 days
  4. Evaluate the safety and tolerability via Blood pressure of Vital SignsTime frame: Up to 58 days
  5. Evaluate the safety and tolerability via Body temperature of Vital SignsTime frame: Up to 58 days
  6. Evaluating the safety and tolerability from Red blood cell count of Laboratory ExaminationTime frame: Up to 58 days
  7. Evaluating the safety and tolerability from White blood cell of Laboratory ExaminationTime frame: Up to 58 days
  8. Evaluating the safety and tolerability from lymphocyte count of Laboratory ExaminationTime frame: Up to 58 days
  9. Evaluating the safety and tolerability from hemoglobin of Laboratory ExaminationTime frame: Up to 58 days
  10. Evaluating the safety and tolerability from Laboratory ExaminationTime frame: Up to 58 days
  11. Evaluating the safety and tolerability from Prothrombin time of Laboratory ExaminationTime frame: Up to 58 days
  12. Evaluating the safety and tolerability from Activated partial thromboplastin time of Laboratory ExaminationTime frame: Up to 58 days
  13. Evaluating the safety and tolerability from total bilirubin concentration of Laboratory ExaminationTime frame: Up to 58 days
  14. Evaluating the safety and tolerability from direct bilirubin concentratio of Laboratory ExaminationTime frame: Up to 58 days
  15. Evaluating the safety and tolerability from ALT of Laboratory ExaminationTime frame: Up to 58 days
  16. Evaluating the safety and tolerability from AST of Laboratory ExaminationTime frame: Up to 58 days
  17. Evaluating the safety and tolerability from creatinine concentration of Laboratory ExaminationTime frame: Up to 58 days
  18. Evaluating the safety and tolerability from triglyceridesconcentration of Laboratory ExaminationTime frame: Up to 58 days
  19. Evaluating the safety and tolerability from urine protein of Laboratory ExaminationTime frame: Up to 58 days
  20. Evaluating the safety and tolerability from urine pH value of Laboratory ExaminationTime frame: Up to 58 days
  21. Evaluating the safety and tolerability from ventricular rate of ElectrocardiogramTime frame: Up to 58 days
  22. Evaluating the safety and tolerability from PR interval of ElectrocardiogramTime frame: Up to 58 days
  23. Evaluating the safety and tolerability from QRS (ms) of ElectrocardiogramTime frame: Up to 58 days
  24. Evaluating the safety and tolerability from QTc of ElectrocardiogramTime frame: Up to 58 days
  25. Evaluate the impact of oral IPG11406 on biomarkers in patients with Lupus NephritisTime frame: Up to 58 days
  26. Evaluate the impact of oral administration of IPG11406 on 24-hour urine protein quantitation of proteinuria and renal function in patients with Lupus NephritisTime frame: Up to 58 days
  27. Evaluate the impact of oral administration of IPG11406 on estimated glomerular filtration rate of proteinuria and renal function in patients with Lupus NephritisTime frame: Up to 58 days
  28. Evaluate the impact of oral administration of IPG11406 on ratio of 24-hour urine protein to urine creatinine of proteinuria and renal function in patients with Lupus NephritisTime frame: Up to 58 days
  29. Evaluate the impact of oral administration of IPG11406 on proteinuria and renal function in patients with Lupus NephritisTime frame: Up to 58 days

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital Of Anhui Medical University

    Hefei, Anhui, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China

  • Sun Yai-sen Memorial Hospital, Sun Yai-sen University

    Guangzhou, Guandong, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • Xinxiang Central Hospital

    Xinxiang, Henan, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Wuhan Hospital of Traditional Chinese and Western Medicine

    Wuhan, Hubei, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Nanjing DrumTower Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Nantong First People's Hospital

    Nantong, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Shandong Provincial Hospital

    Jinan, Shandong, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Jinhua Municipal Centeral Hospital Medical Group

    Jinhua, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.